ClinicalTrials.gg
RecruitingNCT05743049Updated Apr 7, 2026

Collection of Circulating Biomarkers in Pancreatic Cancer

An observational study in Pancreas Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Abramson Cancer Center at Penn Medicine · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Pancreatic Neoplasms by Abramson Cancer Center at Penn Medicine — 3 open to participants now, 4 under way, none of them phase 3. Pancreatic Neoplasms · Abramson Cancer Center at Penn Medicine.

Started
2023
the only one that year
Observational
3 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Pancreatic Neoplasms by Abramson Cancer Center at Penn Medicine, this one is the only one that started in 2023, is one of 3 observational ones, and was the 15th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 16 studies in Pancreatic Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Pancreatic Neoplasms by Abramson Cancer Center at Penn Medicine, or all of them as a file.
02

Study summary

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

03

Conditions studied

  • Pancreas Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

known or suspected diagnosis of pancreatic adenocarcinoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma
  • The subject must be a patient of the University of Pennsylvania
  • The subject must be able to provide
  • The subject must be 18 years of age or older

Exclusion criteria

Exclusion Criteria:

. Subjects who have any psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give are ineligible to participate in the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Blood specimens

    Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma.

    Other: Obtaining blood for analysis of various circulating biomarkers

Interventions

  • OtherObtaining blood for analysis of various circulating biomarkers

    4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period

06

What researchers measure

Primary outcomes

  1. To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response.

    Time frame: Through study completion, an average of 1 year

  2. To integrate the data and specimens to permit the most informative clinical-biologic research platform.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 52 months after the start.

Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 52 months is below that.

Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2023
First posted
Feb 24, 2023
StartActual
Feb 27, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jan 15, 2028
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743049
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Feb 27, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Apr 7, 2026

Study contacts

Liudmila Mazaleuskaya, PhD
Contact
mazali@pennmedicine.upenn.edu
267-455-9141
Mark O'Hara, MD
Contact
Mark.OHara@pennmedicine.upenn.edu
215-360-0919
Mark O'Hara, MD
principal investigator · Abramson Cancer Center, University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion